Rafarma Pharmaceuticals is working on a dietary supplement for the neurological deficits’ treatment
Rafarma Pharmaceuticals, Inc. (OTC: RAFA), where one of the priorities is the anti-aging therapy development, is starting a scientific research program for the post-COVID syndrome therapy. It is proven that the infection provokes and accelerates the aging process of the body but, fortunately, this process is reversible. Given the current prevalence of the disease, the treatment of its sequelae is an important challenge for the entire healthcare system.
The dietary supplement, which the company is working on now, will potentially help eliminate the deficiency of biologically active substances, leading to disruption of the body. The product development is conducted in partnership with the China Traditional Medicine Institute, one of the world’s foremost natural medical universities.
In the first quarter of 2022, the company plans to register studies with regulatory authorities in target markets. In the second quarter of the year, it potentially begins clinical trials. Biologically active dietary supplements will be registered in the markets of North America, the European Union, the CIS, Morocco, Colombia and the Arab States of the Persian Gulf.
ABOUT RAFARMA PHARMACEUTICALS:
Rafarma Pharmaceuticals is an international holding company is engaged in projects conducting the production and market entry of innovative drugs and technology platforms. The business has had a reputation as a reliable manufacturer and distributor since 1930. Rafarma Pharmaceuticals run more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.
For more information, please visit https://www.noyarp.com
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Source: Rafarma Pharmaceuticals, Inc.